Amplifon stock stands 1.73 percent above Xetra close before results

Published on 10/26/2026 at 09:46 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Third-quarter results are due October 29, 2026. Amplifon stock costs EUR 12.92 on October 26, 2026, 1.73 percent above the Xetra close.

Results date and operating progress

Amplifon scheduled its third-quarter 2026 results presentation for October 29, 2026.
Second-quarter revenue rose 2.2 percent to EUR 606.0 million, while net income increased 9.6 percent.
Amplifon stock trades at EUR 12.92 at 9:40 a.m. CEST at Lang & Schwarz on October 26, 2026, 1.73 percent above the Xetra close of October 23, 2026.

Editorial-Foto eines Trading-Floors mit Kurscharts und Healthcare-Sektorkürzel — Börsen-Editorial zeigt Trading-Floor mit Gesundheits-Charts, thematisch verknüpft mit Amplifon S.p.A., ISIN IT0004056880, FTSE MIB gelistet, Illustration mit AI erstellt.

Amplifon stock (ISIN IT0004056880) trades at EUR 12.92 at Lang & Schwarz on October 26, 2026 at 9:40 a.m. CEST, up 1.73 percent versus the Xetra close of October 23, 2026 at EUR 12.70. The next test is the company's third-quarter report scheduled for October 29, 2026, according to Amplifon.

Second-quarter margins improved

Amplifon's latest reported figures give the upcoming release a clear benchmark. In the second quarter of 2026, revenue reached EUR 606.0 million, up 2.20 percent from the same period a year earlier, while net income rose 9.60 percent to EUR 38.6 million, according to Simply Wall St. Amplifon also said adjusted EBITDA increased 6.10 percent and the margin expanded by 90 basis points in its July 30 release, carried on the company homepage.

Three dates shape the 2026 story

On March 16, 2026, Amplifon announced its EUR 2.3 billion acquisition of GN Hearing, according to Amplifon. On July 30, 2026, the company reported second-quarter organic growth of 4.70 percent. On October 9, 2026, Morgan Stanley raised its target from EUR 14.90 to EUR 14.96 while retaining an Overweight rating, as Teleborsa reported.

What will October 29 clarify?

The report can show whether organic growth is holding above the second-quarter rate while profitability continues to benefit from the Fit4Growth program. Morningstar also identified the ended US managed-care agreement as a counter-factor and reported a fair-value estimate of EUR 11.70 on October 21, 2026, according to Morningstar.

Stock approaches its next test

Amplifon has a market capitalization of EUR 2.8 billion and a 52-week range of EUR 7.84 to EUR 15.79, based on October 26, 2026 market figures. The current quote leaves the stock EUR 0.22 above the Xetra close used for the daily comparison.

Amplifon was trading at EUR 12.92 at Lang & Schwarz on October 26, 2026 at 9:40 a.m. CEST, 1.73 percent above the Xetra close of October 23, 2026 at EUR 12.70. The further course of trading is shown by the continuously updated real-time quote of Amplifon stock.